Jada Lewis,
Chair Of Physiological Sciences, Professor Of Physiological Sciences And Neuroscience
Department:
Department of Physiological Sciences
Business Phone:
(352) 273-9666
Business Email:
jada.lewis@ufl.edu
Teaching Profile
Courses Taught
2019-2023
GMS5905 Special Topics in Biomedical Sciences
2019
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2019
GMS6705 Functional Human Neuroanatomy
2018
GMS7980 Research for Doctoral Dissertation
2018,2023-2024
GMS7979 Advanced Research
2013,2015-2017
GMS6750 Molecular Pathobiology of Neural Disease
2011-2015
GMS6792 Neuroscience Graduate Research Seminar
2014
GMS7794 Neuroscience Seminar
2022-2024
GMS6905 Independent Studies in Medical Sciences
2023-2024
GMS6090 Research in Medical Sciences
2023-2024
GMS7795 Special Topics in Neuroscience
2024
GMS6971 Research for Master’s Thesis
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0003-0004-6597
Publications
2024
Identification and Analysis of Axolotl Homologs for Proteins Implicated in Human Neurodegenerative Proteinopathies
Genes.
15(3)
[DOI] 10.3390/genes15030310.
[PMID] 38540368.
2023
Pharmacokinetics of delta-9-tetrahydrocannabinol following acute cannabis smoke exposure in mice; effects of sex, age, and strain.
Frontiers in pharmacology.
14
[DOI] 10.3389/fphar.2023.1227220.
[PMID] 37701025.
2023
Progressive tauopathy disrupts breathing stability and chemoreflexes during presumptive sleep in mice.
Frontiers in physiology.
14
[DOI] 10.3389/fphys.2023.1272980.
[PMID] 37811498.
2022
Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse Aβ plaque pathology when injected into newborn mouse hosts.
Free neuropathology.
3(9)
[DOI] 10.17879/freeneuropathology-2022-3766.
[PMID] 35494163.
2022
TAPPing into the potential of inducible tau/APP transgenic mice
Neuropathology and Applied Neurobiology.
48(3)
[DOI] 10.1111/nan.12791.
2021
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
Molecular therapy : the journal of the American Society of Gene Therapy.
29(2):859-872
[DOI] 10.1016/j.ymthe.2020.10.007.
[PMID] 33128896.
2021
Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions.
Acta neuropathologica.
141(3):359-381
[DOI] 10.1007/s00401-021-02264-9.
[PMID] 33496840.
2020
Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis.
Acta neuropathologica communications.
8(1)
[DOI] 10.1186/s40478-020-00911-y.
[PMID] 32252825.
2020
Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy.
Molecular neurobiology.
57(4):1986-2001
[DOI] 10.1007/s12035-019-01859-4.
[PMID] 31903524.
2018
Analysis of spinal and muscle pathology in transgenic mice overexpressing wild-type and ALS-linked mutant MATR3
Acta Neuropathologica Communications.
6(1)
[DOI] 10.1186/s40478-018-0631-0.
[PMID] 30563574.
2018
Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.
Acta neuropathologica.
136(6):919-938
[DOI] 10.1007/s00401-018-1895-y.
[PMID] 30140941.
2018
Characterization of gene regulation and protein interaction networks for Matrin 3 encoding mutations linked to amyotrophic lateral sclerosis and myopathy.
Scientific reports.
8(1)
[DOI] 10.1038/s41598-018-21371-4.
[PMID] 29511296.
2018
Designing antibodies against LRRK2-targeted tau epitopes.
PloS one.
13(9)
[DOI] 10.1371/journal.pone.0204367.
[PMID] 30261006.
2018
Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology.
Molecular neurodegeneration.
13(1)
[DOI] 10.1186/s13024-018-0253-9.
[PMID] 29776378.
2018
Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.
PLoS biology.
16(12)
[DOI] 10.1371/journal.pbio.2006265.
[PMID] 30571694.
2018
Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis.
Molecular and cellular neurosciences.
92:17-26
[DOI] 10.1016/j.mcn.2018.05.009.
[PMID] 29859891.
2017
A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking.
PloS one.
12(5)
[DOI] 10.1371/journal.pone.0173565.
[PMID] 28467418.
2016
Generation of a new transgenic mouse model for assessment of tau gene silencing therapies.
Alzheimer's research & therapy.
8(1)
[DOI] 10.1186/s13195-016-0202-1.
[PMID] 27593210.
2016
Heterogeneity of Matrin 3 in the developing and aging murine central nervous system.
The Journal of comparative neurology.
524(14):2740-52
[DOI] 10.1002/cne.23986.
[PMID] 26878116.
2016
Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Acta neuropathologica.
131(1):27-48
[DOI] 10.1007/s00401-015-1507-z.
[PMID] 26576562.
2016
RETRACTED ARTICLE: Transgenic mice overexpressing the ALS-linked protein Matrin 3 develop a profound muscle phenotype
Acta Neuropathologica Communications.
4(1)
[DOI] 10.1186/s40478-016-0393-5.
[PMID] 27863507.
2015
IFN-γ promotes τ phosphorylation without affecting mature tangles.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
29(10):4384-98
[DOI] 10.1096/fj.15-275834.
[PMID] 26156074.
2015
Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission.
Acta neuropathologica.
130(2):303-5
[DOI] 10.1007/s00401-015-1444-x.
[PMID] 25982997.
2015
Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Journal of neuroscience research.
93(10):1567-80
[DOI] 10.1002/jnr.23614.
[PMID] 26123245.
2015
Studies of alternative isoforms provide insight into TDP-43 autoregulation and pathogenesis.
RNA (New York, N.Y.).
21(8):1419-32
[DOI] 10.1261/rna.047647.114.
[PMID] 26089325.
2015
Subcellular Localization of Matrin 3 Containing Mutations Associated with ALS and Distal Myopathy.
PloS one.
10(11)
[DOI] 10.1371/journal.pone.0142144.
[PMID] 26528920.
2014
Age-related decline in white matter integrity in a mouse model of tauopathy: an in vivo diffusion tensor magnetic resonance imaging study.
Neurobiology of aging.
35(6):1364-74
[DOI] 10.1016/j.neurobiolaging.2013.12.009.
[PMID] 24411290.
2014
Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling.
PloS one.
9(1)
[DOI] 10.1371/journal.pone.0086513.
[PMID] 24466128.
2014
Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.
Molecular neurodegeneration.
9
[DOI] 10.1186/1750-1326-9-8.
[PMID] 24428919.
2014
ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.
Nature communications.
5
[DOI] 10.1038/ncomms4996.
[PMID] 24893131.
2014
Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation.
PloS one.
9(1)
[DOI] 10.1371/journal.pone.0087383.
[PMID] 24489906.
2014
Tau promotes neurodegeneration through global chromatin relaxation.
Nature neuroscience.
17(3):357-66
[DOI] 10.1038/nn.3639.
[PMID] 24464041.
2014
Therapeutic and diagnostic challenges for frontotemporal dementia.
Frontiers in aging neuroscience.
6
[DOI] 10.3389/fnagi.2014.00204.
[PMID] 25191265.
2014
Understanding the Role of Progranulin in Alzheimer’s Disease
.
20(10):1099-1100
2014
Understanding the role of progranulin in Alzheimer’s disease.
Nature medicine.
20(10):1099-100
[DOI] 10.1038/nm.3712.
[PMID] 25295938.
2013
Anti-tau antibodies: hitting the target.
Neuron.
80(2):254-6
[DOI] 10.1016/j.neuron.2013.10.009.
[PMID] 24139027.
2013
Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.
Human molecular genetics.
22(10):2067-82
[DOI] 10.1093/hmg/ddt057.
[PMID] 23393156.
2013
Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.
Journal of Alzheimer's disease : JAD.
33(1):249-63
[DOI] 10.3233/JAD-2012-121093.
[PMID] 22941973.
2013
Conformational templating of α-synuclein aggregates in neuronal-glial cultures.
Molecular neurodegeneration.
8
[DOI] 10.1186/1750-1326-8-17.
[PMID] 23714769.
2013
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
Neuron.
79(6):1094-108
[DOI] 10.1016/j.neuron.2013.07.037.
[PMID] 24050400.
2013
In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures.
Molecular neurodegeneration.
8
[DOI] 10.1186/1750-1326-8-9.
[PMID] 23379588.
2013
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.
Acta neuropathologica.
126(6):809-27
[DOI] 10.1007/s00401-013-1188-4.
[PMID] 24113872.
2013
LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer’s disease (LOAD).
PloS one.
8(6)
[DOI] 10.1371/journal.pone.0064164.
[PMID] 23750206.
2013
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia.
Proceedings of the National Academy of Sciences of the United States of America.
110(51):E4968-77
[DOI] 10.1073/pnas.1315438110.
[PMID] 24248382.
2013
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Acta neuropathologica.
126(1):39-50
[DOI] 10.1007/s00401-013-1123-8.
[PMID] 23666556.
2013
Thinking laterally about neurodegenerative proteinopathies.
The Journal of clinical investigation.
123(5):1847-55
[DOI] 10.1172/JCI66029.
[PMID] 23635781.
2013
Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions.
Brain research.
1524:62-73
[DOI] 10.1016/j.brainres.2013.06.006.
[PMID] 23774650.
2012
Achievements and Challenges in Creating Animal Models of Frontotemporal Dementias
Dementia and Geriatric Cognitive Disorders.
33:5-6
2012
Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction.
Acta neuropathologica.
123(6):807-23
[DOI] 10.1007/s00401-012-0979-3.
[PMID] 22539017.
2012
Progranulin regulates neuronal outgrowth independent of sortilin.
Molecular neurodegeneration.
7
[DOI] 10.1186/1750-1326-7-33.
[PMID] 22781549.
2012
Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.
American journal of human genetics.
90(6):1102-7
[DOI] 10.1016/j.ajhg.2012.04.021.
[PMID] 22608501.
2011
Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.
Molecular neurodegeneration.
6
[DOI] 10.1186/1750-1326-6-73.
[PMID] 22029574.
2011
Homeostatic responses by surviving cortical pyramidal cells in neurodegenerative tauopathy.
Acta neuropathologica.
122(5):551-64
[DOI] 10.1007/s00401-011-0877-0.
[PMID] 21968531.
2011
Structural abnormalities in the cortex of the rTg4510 mouse model of tauopathy: a light and electron microscopy study.
Brain structure & function.
216(1):31-42
[DOI] 10.1007/s00429-010-0295-4.
[PMID] 21152933.
2010
Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging.
The American journal of pathology.
177(1):311-24
[DOI] 10.2353/ajpath.2010.090915.
[PMID] 20522652.
2010
Amyloid precursor protein and tau transgenic models of Alzheimer’s disease: insights from the past and directions for the future.
Future neurology.
5(3):411-420
[PMID] 20730022.
2010
Sorting out frontotemporal dementia?
Neuron.
68(4):601-3
[DOI] 10.1016/j.neuron.2010.11.014.
[PMID] 21092851.
2010
Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs.
Experimental neurology.
223(2):385-93
[DOI] 10.1016/j.expneurol.2009.07.029.
[PMID] 19665462.
2010
Targeting Abeta and tau in Alzheimer’s disease, an early interim report.
Experimental neurology.
223(2):252-66
[DOI] 10.1016/j.expneurol.2009.07.035.
[PMID] 19716367.
2010
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
30(32):10851-9
[DOI] 10.1523/JNEUROSCI.1630-10.2010.
[PMID] 20702714.
2009
Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.
The American journal of pathology.
174(1):228-38
[DOI] 10.2353/ajpath.2009.080764.
[PMID] 19074615.
2009
Aging is not associated with proteasome impairment in UPS reporter mice.
PloS one.
4(6)
[DOI] 10.1371/journal.pone.0005888.
[PMID] 19517018.
2008
A novel calcium-binding protein is associated with tau proteins in tauopathy.
Journal of neurochemistry.
106(1):96-106
[DOI] 10.1111/j.1471-4159.2008.05339.x.
[PMID] 18346207.
2008
Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice.
Journal of Alzheimer's disease : JAD.
15(4):605-14
[PMID] 19096159.
2008
Apparent behavioral benefits of Tau overexpression in P301L Tau transgenic miceIn vivo silencing of alpha-synuclein using naked siRNA
.
15(4):605-614
2008
Biologic models of neurodegenerative disorders.
Handbook of clinical neurology.
89:173-88
[DOI] 10.1016/S0072-9752(07)01216-X.
[PMID] 18631742.
2008
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
28(4):862-7
[DOI] 10.1523/JNEUROSCI.3072-08.2008.
[PMID] 18216194.
2008
In vivo silencing of alpha-synuclein using naked siRNA.
Molecular neurodegeneration.
3
[DOI] 10.1186/1750-1326-3-19.
[PMID] 18976489.
2007
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
27(14):3650-62
[PMID] 17409229.
2007
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice.
The American journal of pathology.
171(6):2012-20
[PMID] 18055549.
2006
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.
Proceedings of the National Academy of Sciences of the United States of America.
103(25):9673-8
[PMID] 16769887.
2006
Neurofibrillary tangle-related synaptic alterations of spinal motor neurons of P301L tau transgenic mice.
Neuroscience letters.
409(2):95-9
[PMID] 17010516.
2005
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
The Journal of neuroscience : the official journal of the Society for Neuroscience.
25(46):10637-47
[PMID] 16291936.
2005
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Proceedings of the National Academy of Sciences of the United States of America.
102(19):6990-5
[PMID] 15867159.
2005
Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau.
Journal of neurocytology.
34(6):397-410
[PMID] 16902761.
2005
Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
25(5):1226-33
[PMID] 15689560.
2005
Tau suppression in a neurodegenerative mouse model improves memory function.
Science (New York, N.Y.).
309(5733):476-81
[PMID] 16020737.
2004
Apoptosis in oligodendrocytes is associated with axonal degeneration in P301L tau mice.
Neurobiology of disease.
15(3):553-62
[PMID] 15056463.
2004
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.
Human molecular genetics.
13(7):703-14
[PMID] 14962978.
2004
Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer’s disease: linkage of poorer cognitive performance to tau pathology in forebrain.
Brain research.
1012(1-2):29-41
[PMID] 15158158.
2004
Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Journal of neurochemistry.
90(4):829-38
[PMID] 15287888.
2004
Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau.
The American journal of pathology.
164(1):347-53
[PMID] 14695347.
2004
The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer’s transgenic mice.
Neuroreport.
15(1):73-7
[PMID] 15106834.
2003
Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.
The American journal of pathology.
163(3):1057-67
[PMID] 12937146.
2003
Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation.
The American journal of pathology.
162(1):213-8
[PMID] 12507904.
2003
Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Journal of neurocytology.
32(9):1091-105
[PMID] 15044841.
2002
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Journal of neurochemistry.
83(6):1498-508
[PMID] 12472903.
2001
Analysis of tauopathies with transgenic mice.
Trends in molecular medicine.
7(10):467-70
[PMID] 11597522.
2001
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.
Science (New York, N.Y.).
293(5534):1487-91
[PMID] 11520987.
2001
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles.
Science (New York, N.Y.).
293(5530):711-4
[PMID] 11408621.
2000
Animal Models of tau dysfunction
Neuroscience.
3(5):63-72
2000
Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions.
Brain research.
853(1):5-14
[PMID] 10627302.
2000
Neurofibrillary tangles, amyotrophy, and progressive motor impairment in Tau mutant (P301L) transgenic mice
Nature Genetics.
25:402-405
2000
The molecular genetics of the tauopathies.
Experimental gerontology.
35(4):461-71
[PMID] 10959034.
1999
5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10.
The Journal of biological chemistry.
274(21):15134-43
[PMID] 10329720.
1999
Accelerated filament formation from tau protein with specific FTDP-17 missense mutations.
FEBS letters.
447(2-3):195-9
[PMID] 10214944.
1998
A common human beta globin splicing mutation modeled in mice.
Blood.
91(6):2152-6
[PMID] 9490703.
1998
Rapid genotyping of mice with hemoglobinopathies and globin transgenes.
Biochemical genetics.
36(1-2):65-77
[PMID] 9562907.
1996
Gene modification via “plug and socket” gene targeting.
The Journal of clinical investigation.
97(1):3-5
[PMID] 8550847.
1995
A mouse model for beta 0-thalassemia.
Proceedings of the National Academy of Sciences of the United States of America.
92(25):11608-12
[PMID] 8524813.
1994
Deletion and replacement of the mouse adult beta-globin genes by a “plug and socket” repeated targeting strategy.
Molecular and cellular biology.
14(10):6936-43
[PMID] 7935410.
Grants
May 2024
ACTIVE
Clinical and Translational Pre-doctoral training in Alzheimers Disease and Related Dementias
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Aug 2023
– Jun 2024
Immunotherapy targeting the HPA axis in Alzheimers disease
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIA
Sep 2022
– Aug 2024
A Systems Approach to Targeting Innate Immunity in AD
Role: Principal Investigator
Funding: MAYO CLINIC
via NATL INST OF HLTH NIA
Apr 2022
ACTIVE
Characterization of new CamK2-tau strains of mice to model dementia
Role: Principal Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Feb 2022
ACTIVE
Contributions of tau-mediated translational dysregulation to pathogenesis and progression of fronto-temporal dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2021
ACTIVE
Developing new conditional models to study tauopathy, amyloidosis, and their interaction
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2021
ACTIVE
Effects of cannabis on age-related cognitive decline and Alzheimers disease pathology
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
May 2021
– Feb 2023
Effects of cannabis on Alzheimers disease-related pathology and cognitive decline
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Sep 2019
– Aug 2021
Developing new conditional models to study tauopathy, amyloidosis, and their interaction
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2019
– Jun 2024
Elucidating factors that modulate tauopathy and cellular degeneration to guide therapeutic development
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Aug 2019
– Jul 2022
Immunotherapy targeting the HPA axis in Alzheimers disease
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Mar 2019
– Feb 2021
The Two Faces of Hypoxia in Alzheimer's Disease
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Sep 2018
– Apr 2024
Clinical and Translational Pre-doctoral training in Alzheimers Disease and Related Dementias
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Jun 2018
– Aug 2023
APOE as a modifier of prion-like spread in dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017
– May 2018
APOE as a modifier of prion-like spread in dementia
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2017
– Jun 2020
Uncovering targets that block pathological interactions between Abeta and tau
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Mar 2017
– Feb 2024
Towards understanding the role of immune regulation of Apolipoprotein E function in Alzheimers disease proteostasis
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Feb 2017
– Sep 2019
Large-scale identification of genes that suppress concurrent Abeta42 and tau pathology in vivo
Role: Co-Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Dec 2016
– Nov 2019
Is there a form of benign brain amyloidosis in aging?
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Aug 2016
– Sep 2019
New mouse models to dissect out the function of the ALS-associated protein Matrin 3
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Aug 2015
– May 2021
University of Florida – Mt. Sinai Medical Center AD Research Center
Role: Co-Project Director/Principal Investigator
Funding: NATL INST OF HLTH NIA
Jul 2015
– Jun 2018
Towards a knockdown therapy for tauopathy
Role: Principal Investigator
Funding: BRIGHTFOCUS FOU
Apr 2015
– Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Jul 2014
– Jun 2017
Optogenetic modeling of primary and secondary CNS proteinopathies in Drosophila
Role: Project Manager
Funding: NATL INST OF HLTH NINDS
Apr 2014
– Mar 2016
Einstein Aging Study Neuropathology Core
Role: Principal Investigator
Funding: MAYO CLINIC
via NATL INST OF HLTH
Jul 2013
– Jun 2018
Biological and Pathological Interactions between Tau and LRRK2
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2010
– Jun 2023
Animal Models in neurodegenerative Disease
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO
Contact Details
Phones:
- Business:
- (352) 273-9666
Emails:
- Business:
- jada.lewis@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100144
GAINESVILLE FL 32610 - Business Street:
-
1333 Center Drive
GAINESVILLE FL 32603